# Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

> **NCT07017673** · PHASE2 · RECRUITING · sponsor: **Cedars-Sinai Medical Center** · enrollment: 34 (estimated)

## Conditions studied

- TNBC
- TNBC - Triple-Negative Breast Cancer
- Early Stage Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** Carboplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07017673
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-12
- **Final completion:** 2032-11
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017673, "Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07017673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*